Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) retreated -1.1% and closed its last session at $8.95. The stock has the market capitalization of $626.95 Million with the total outstanding shares of 70.05 Million. Progenics Pharmaceuticals, Inc.. has Analysts’ Mean Recommendation of 1 between the scale of 1 to 5 (1 represents Strong Buy and 5 means Sell). The stock currently has P/E of 57.37 for trailing twelve months while its Forward P/E is 0.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) touched its 52-Week High of $9.23 on Nov 30, 2016 while it’s 52-Week Low of $3.61 on Feb 9, 2016. The company currently has Return on Assets of 8.2 percent, Return on Equity of 12.3% and Return on Investment of -43.3 percent. The stock currently showing Weekly Volatility of 4.63%% and Monthly Volatility of 6.96% Percent with Average True Range of 0.41 and Beta of 3.08.
The 5 analysts offering 12-month price forecasts for Progenics Pharmaceuticals Inc have a median target of 11.00, with a high estimate of 12.00 and a low estimate of 9.00. The median estimate represents a +22.91% increase from the last price of 8.95.
The Company on 7 November declared financial results for the third quarter 2016 and business update.
Key Business Highlights
RELISTOR, treatment for opioid-induced constipation (partnered with Valeant Pharmaceuticals International, Inc.)
- Declared Food and Drug Administration (FDA) Approval and Commercial Launch of Oral RELISTOR for the Treatment of Opioid Induced Constipation in Adults with Chronic Non-Cancer Pain. The approval triggered a $50 million milestone payment on July 25 from Progenics’ commercialization partner, Valeant, as well as subsequent royalties and the potential of up to $200 million in sales milestones.
- RELISTOR (SC and Oral) Net Sales for the Third of 2016 Totaled $22.1 million. The third quarter 2016 sales, as reported to Progenics by Valeant, translated to $3.3 million in royalty revenue for the quarter.
AZEDRA, Ultra-orphan radio therapeutic candidate
- AZEDRA Topline Results Expected First Quarter 2017. In early 2017, Progenics expects to report topline results from its ongoing registration trial of AZEDRA. If the AZEDRA trial meets the endpoints of the Special Protocol Assessment (SPA), Progenics expects to submit a New Drug Application (NDA) to the FDA during the first half of 2017.
Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics’ first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics’ first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc.